Twist Bioscience Q4 revenue beats analyst expectations
TWST•Twist Bioscience reported Q4 revenue of $459.40 million, beating analyst expectations, and a loss per share of $0.32. It expects FY27 revenue of approximately $550 million to $560 million and targets a gross margin of 52.5% to 53%.
1. Quarterly results
Twist Bioscience reported fiscal fourth-quarter revenue of $459.40 million, listed as a beat against analyst expectations, and a loss per share of $0.32.
2. FY27 outlook
The company expects FY27 revenue of approximately $550 million to $560 million, up approximately 21% at the midpoint. It expects Q1 FY27 revenue of approximately $130 million to $132 million, up approximately 26% at the midpoint, and targets a FY27 gross margin of approximately 52.5% to 53%, positive adjusted EBITDA and approximately $75 million in capital expenditure.
3. Annual results
FY2026 DNA Synthesis and Protein Solutions revenue rose 31.7% to $221.9 million, while NGS Applications revenue increased 14.1% to $237.5 million. The FY net loss widened to $130.2 million from $77.7 million; the company cited a $48.8 million business-sale gain in FY2025 and $7.2 million in FY2026 litigation costs.
